XNW5004

DRUG2 trials

Sponsors

Evopoint Biosciences Inc.

Conditions

CarcinomaCervical CancerMetastatic Castrate-Resistant Prostate CancerNon-small Cell Lung CancerOther Solid TumorsProstate CancerSmall-cell Lung CancerSquamous Cell Carcinoma of Head and Neck

Phase 1

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

TerminatedNCT06022757

Evopoint Biosciences Inc.Carcinoma, Cervical Cancer, Non-small Cell Lung Cancer +5

Start: 2023-09-20End: 2025-01-13Updated: 2026-07-23

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT06702995

Evopoint Biosciences Inc.mCRPC (Metastatic Castration-resistant Prostate Cancer), Metastatic Castrate-Resistant Prostate Cancer

Start: 2023-04-19End: 2026-07-19Target: 307Updated: 2025-04-20